The identification of PKCδ and DNA-PKcs as subtype-specific MKs from SPHINKS-inferred PG, BRCA and LSCC kinase–phosphosite interactomes delivers targeted therapeutic directions for GPM and PPR subtypes across multiple tumor types. The gene discussed is PRKCD; the disease is neoplasm.